Acute kidney injury following colistin treatment in critically-ill patients: may glucocorticoids protect?

References

• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005 May 1;40(9):1333–41.
   PubMed Web of Science ®Google Scholar
• Catry B, Cavaleri M, Baptiste K, Grave K, Grein K, Holm A, et al. Use of colistin-containing products within the European Union and European Economic Area (EU/EEA): development of resistance in animals and possible impact on human and animal health. Int J Antimicrob Agents. 2015 Sep;46(3):297–306.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009 Dec 2;302(21):2323–9.
   PubMed Web of Science ®Google Scholar
• Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011;1(1):14.
   PubMed Web of Science ®Google Scholar
• Meraz-Muñoz A, Gomez-Ruiz I, Correa-Rotter R, Ramirez-Sandoval JC. Chronic kidney disease after acute kidney injury associated with intravenous colistin use in survivors of severe infections: a comparative cohort study. J Crit Care. 2018 Apr;44:244–8.
   PubMed Web of Science ®Google Scholar
• Fiaccadori E, Antonucci E, Morabito S, d'Avolio A, Maggiore U, Regolisti G. Colistin use in patients with reduced kidney function. Am J Kidney Dis. 2016 Aug;68(2):296–306.
   PubMed Web of Science ®Google Scholar
• Omrani AS, Alfahad WA, Shoukri MM, Baadani AM, Aldalbahi S, Almitwazi AA, et al. High dose intravenous colistin methanesulfonate therapy is associated with high rates of nephrotoxicity; a prospective cohort study from Saudi Arabia. Ann Clin Microbiol Antimicrob. 2015;14:3.
   PubMed Web of Science ®Google Scholar
• Inci A, Toker MK, Bicer IG, Derbent A, Salihoglu Z. Determination of colistin-related nephrotoxicity and risk factors in intensive care unit. North Clin Istanb. 2018;5(2):120–4.
   PubMed Web of Science ®Google Scholar
• Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol. 2015 Jul;71(7):801–10.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, di Masi A, Leboffe L, Del Bono V, Rossi M, Cappiello D, et al. Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment. Sci Rep. 2018;8(1):11968.
   PubMedGoogle Scholar
• Shields RK, Anand R, Clarke LG, Paronish JA, Weirich M, Perone H, et al. Defining the incidence and risk factors of colistin-induced acute kidney injury by KDIGO criteria. PLoS One. 2017;12(3):e0173286.
   PubMed Web of Science ®Google Scholar
• Dalfino L, Puntillo F, Ondok MJM, Mosca A, Monno R, Coppolecchia S, et al. Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study. Clin Infect Dis. 2015 Dec 15;61(12):1771–7.
   PubMed Web of Science ®Google Scholar
• Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55(7):3284–94.
   PubMed Web of Science ®Google Scholar
• Viscoli C. Bloodstream infections: the peak of the iceberg. Virulence. 2016;7(3):248–51.
   PubMed Web of Science ®Google Scholar
• Ats I. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
   PubMed Web of Science ®Google Scholar
• Chen Z, Chen Y, Fang Y, Wang X, Chen Y, Qi Q, et al. Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Sci Rep. 2015;5(1):17091.
   PubMedGoogle Scholar
• Levey AS, Stevens LA, Schmid CH, Zhang Y(L), Castro AF, Feldman HI, et al. CKD-EPI (chronic kidney disease epidemiology collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
   PubMed Web of Science ®Google Scholar
• Kellum JA, Lameire N, KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204.
   PubMed Web of Science ®Google Scholar
• Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol. 2020 Feb;31(2):435–46.
   PubMed Web of Science ®Google Scholar
• Chien HT, Lin YC, Sheu CC, Hsieh KP, Chang JS. Is colistin-associated acute kidney injury clinically important in adults? A systematic review and meta-analysis. Int J Antimicrob Agents. 2020 Mar;55(3):105889.
   PubMed Web of Science ®Google Scholar
• Lee SH, Kim JS, Ravichandran K, Gil HW, Song HY, Hong SY. P-Glycoprotein induction ameliorates colistin induced nephrotoxicity in cultured human proximal tubular cells. PLoS One. 2015;10(8):e0136075.
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Andini R, Signoriello S, Cavezza G, Murino P, Buono S, et al. Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections. Clin Microbiol Infect. 2016 Dec;22(12):984–9.
   PubMed Web of Science ®Google Scholar
• Xu X, Nie S, Zhang A, Mao J, Liu HP, Xia H, et al. Acute kidney injury among hospitalized children in China. Clin J Am Soc Nephrol. 2018 Oct 4;13(12):1791–800.
   PubMed Web of Science ®Google Scholar
• Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy. 2019 Apr;39(4):443–53.
   PubMed Web of Science ®Google Scholar
• Al-Aly Z, Maddukuri G, Xie Y. Proton pump inhibitors and the kidney: implications of current evidence for clinical practice and when and how to deprescribe. Am J Kidney Dis. 2019 Oct 10;75(4):497–507.
   PubMed Web of Science ®Google Scholar
• Santana-Santos E, Gowdak LHW, Gaiotto FA, Puig LB, Hajjar LA, Zeferino SP, et al. High dose of N-acetylcystein prevents acute kidney injury in chronic kidney disease patients undergoing myocardial revascularization. Ann Thorac Surg. 2014 May;97(5):1617–23.
   PubMed Web of Science ®Google Scholar
• Pierce B, Bole I, Patel V, Brown DL. Clinical outcomes of remote ischemic preconditioning prior to cardiac surgery: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2017;6(2):e004666.
   PubMed Web of Science ®Google Scholar
• Aydoğan BB, Yıldırım F, Zerman A, Gönderen K, Türkoğlu M, Aygencel G. Colistin nephrotoxicity in the ICU: is it different in the geriatric patients? Aging Clin Exp Res. 2018 Jun;30(6):573–80.
   PubMed Web of Science ®Google Scholar
• Pintado V, San Miguel LG, Grill F, Mejía B, Cobo J, Fortún J, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect. 2008 Mar;56(3):185–90.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010 Feb;35(2):194–9.
   PubMed Web of Science ®Google Scholar
• Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2010 Mar;35(3):297–300.
   PubMed Web of Science ®Google Scholar
• Miano TA, Lautenbach E, Wilson FP, Guo W, Borovskiy Y, Hennessy S. Attributable risk and time course of colistin-associated acute kidney injury. Clin J Am Soc Nephrol. 2018 Apr 6;13(4):542–50.
   PubMed Web of Science ®Google Scholar
• Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53(9):879–84.
   PubMed Web of Science ®Google Scholar
• Kwon J-A, Lee JE, Huh W, Peck KR, Kim Y-G, Kim DJ, et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents. 2010;35(5):473–7.
   PubMed Web of Science ®Google Scholar
• Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother. 2012 May;56(5):2392–6.
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Oliveira MS, Perdigão-Neto LV, Levin AS, Carrilho CM, Tanita MT, et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother. 2016;60(4):2443–9.
   PubMed Web of Science ®Google Scholar
• Okoduwa A, Ahmed N, Guo Y, Scipione MR, Papadopoulos J, Eiras DP, et al. Nephrotoxicity associated with intravenous polymyxin B once- versus twice-daily dosing regimen. Antimicrob Agents Chemother. 2018;62(8):e00025–18.
   PubMed Web of Science ®Google Scholar
• Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents. 2014 Apr;43(4):349–52.
   PubMed Web of Science ®Google Scholar
• Hassan MM, Gaifer Z, Al-Zakwani IS. Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium. Int J Clin Pharm. 2018 Apr;40(2):444–9.
   PubMed Web of Science ®Google Scholar